Moderna Inc. (NASDAQ: MRNA) has undergone a remarkable technical transformation, shifting from a prolonged bearish trend into what appears to be a new bullish structure.

After reclaiming a critical resistance level, MRNA has surged by over 450%, breaking through several major technical barriers along the way.📈

📊 Technical Outlook

For several years, MRNA traded within the falling channel marked in orange, consistently forming lower highs and lower lows.

However, the technical picture began to change when the stock broke above its last major high around $38, marked in blue, which aligned closely with the 50-week EMA.

This breakout represented an important shift in the broader market structure, providing an early indication that the bulls were beginning to regain control.

Since then, MRNA has experienced an impressive bullish expansion, gaining more than 450% from that key area.📈

More importantly, the advance has been supported by a series of consecutive technical breakouts.

First, MRNA cleared the $60 resistance, followed by a breakout above the upper boundary of the orange falling channel, signaling a potential end to the previous bearish structure.

The bullish momentum then carried the stock above the $115 resistance, before recently pushing through the $220 resistance, the third major level highlighted on the chart.

🐂 What’s Next for MRNA?

The $220 level is now the key area to monitor.

Following the recent breakout, this former resistance could potentially turn into support.

As long as MRNA manages to hold above $220, the broader bullish structure would remain intact, opening the possibility of further upside toward the historical $500 all-time-high region.🎯

A sustained move above $220 would strengthen this scenario, while a failure to defend the breakout could lead to a correction toward previous support levels.

Importantly, $500 represents a longer-term technical objective rather than a guaranteed target or an immediate price projection.

🧬 Fundamental Outlook

Beyond the technical picture, Moderna’s recent fundamental developments may help explain the remarkable bullish momentum behind MRNA’s rally.

In August 2026, Moderna and Merck announced a major clinical milestone after their Phase 3 melanoma trial demonstrated positive results for the personalized cancer therapy intismeran autogene in combination with KEYTRUDA.

The treatment achieved statistically significant improvements in recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone.

The announcement triggered a powerful market reaction, with MRNA reportedly surging approximately 177% in a single trading session.📊

This development has strengthened investor optimism about Moderna’s potential to expand beyond its COVID-19 vaccine business into personalized cancer treatments, although regulatory approval remains pending.

From a financial perspective, Moderna reported $145 million in Q2 2026 revenue and maintained its outlook for up to 10% revenue growth in 2026, while improving its operating expense and year-end cash projections.

🎯 Final Thoughts

MRNA has already cleared several major resistance levels, suggesting that the broader technical structure has shifted in favor of the bulls.

The key question now is whether $220 can establish itself as support.

If buyers successfully defend this level, the longer-term bullish scenario could remain active, with the $500 historical high representing the next major upside area to watch.

⚠️Disclaimer: This analysis is for educational and informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. All trading and investing involve risk. Always conduct your own research and manage your exposure accordingly.